Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Toripalimab-tpzi

(Loqtorzi®)

Loqtorzi®

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 240 mg/6 mL [40 mg/mL])
Drug ClassProgrammed death receptor-1 (PD-1) blocking antibodies
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC)
  • Indicated as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Toripalimab plus gemcitabine-cisplatin (GP) improved overall survival (OS) in patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (R/M-NPC) compared to placebo plus GP. The hazard ratio (HR) was 0.59, with a 95% confidence interval (CI) of 0.37 to 0.95.
  • Tislelizumab plus GP was more effective than placebo plus GP in improving Progression-Free Survival (PFS), with an HR of 0.50 (95% CI: 0.37–0.67) and a 1-year PFS rate relative risk (RR) of 3.00 (95% CI: 1.84–5.22). It also demonstrated the best objective response rate (ORR) with an RR of 1.26 (95% CI: 1.04–1.53).
  • While toripalimab plus GP was more cost-effective (Incremental Cost-Utility Ratio (ICUR) of $25,576 per Quality-Adjusted Life Year (QALY)), tislelizumab plus GP showed better overall PFS, 1-year PFS rate, and ORR in comparison to toripalimab plus GP.
  • Tislelizumab plus GP demonstrated a more favorable safety profile compared to toripalimab plus GP, with fewer high-grade Adverse Events (AEs), treatment-related Serious Adverse Events (SAEs), and AEs leading to discontinuation of treatment.
  • Tislelizumab plus GP also reported lower incidences of grade ≥3 AEs and treatment-related AEs grade ≥3 compared to toripalimab plus GP, making it a safer option among the chemotherapy-immunotherapy combinations tested.
  • The studies focused on patients with R/M-NPC, but no specific findings or outcomes were reported regarding different population subgroups such as age, gender, or comorbidities. There is no population type or subgroup information available in the reviewed documents.